The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Treatment status and economic burden of breast cancer targeted drugs in Fujian Province
Author(s): 
Pages: 673-676
Year: Issue:  11
Journal: Qilu Pharmaceutical Affairs

Keyword:  Breast cancerTargeted drugsMedical insurance;
Abstract: Objective To explore the current status of breast cancer targeted drug therapy in Fujian Province,and ana-lyze the economic burden of the treatment,so to provide a reference for the establishment of medical insurance policy of ma-jor catastrophic disease.Methods Obtaining the breast cancer patients' data during 2012 to 2014 from informational system of nine cities' medical insurance management center in Fujian Province;Operating investigation in Guangxi,Guangzhou, Zhuhai,Xiamen and other areas;Holding symposium with experts,scholars and cancer patients.Results In recent years, the incidence of breast cancer in Fujian Province increased year by year. The incidences in 2012,2013 and 2014 were 51. 70,53.76 and 54.26 per 100 000 people,respectively.The incidence for women who aged from 21 to 40 was particularly increased,from 9.13 per 100 000 in 2012 to 10.17 per 100 000 in 2014.The patients' economic burden was heavy,and the cost of targeted drug therapy reached to ¥ 227 000 per patient.Conclusion The key to reduce the economic burden of pa-tients with breast cancer and other serious illness was to improve the medical insurance system for major catastrophic dis-ease,and reduce the cost of targeted drugs.
Related Articles
No related articles found